

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K/A  
(Amendment No. 1)**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 12, 2019**

---



**FIBROCELL SCIENCE, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

**DELAWARE**

(State or Other Jurisdiction of Incorporation or Organization)

**001-31564**

(Commission File No.)

**87-0458888**

(I.R.S. Employer Identification No.)

**405 EAGLEVIEW BLVD., EXTON, PA 19341**

(Address of principal executive offices and zip code)

**(484) 713-6000**

(Registrant's telephone number, including area code)

(Former name or former address, if changed from last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class             | Trading Symbol(s) | Name of each exchange on which registered |
|---------------------------------|-------------------|---|
| Common Stock, par value \$0.001 | FCSC              | The Nasdaq Stock Market LLC               |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

## EXPLANATORY NOTE

On June 14, 2019, Fibrocell Science, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Report”) to, among other things, report on the voting results of its Annual Meeting of Stockholders held on June 12, 2019 (the “Annual Meeting”), including, among other matters, the results of the non-binding advisory vote of the stockholders on the frequency of future advisory votes on the compensation of the Company’s named executive officers. This Amendment No. 1 to Current Report on Form 8-K/A (the “Amendment”) is being filed to disclose the Company’s decision as to how frequently it will hold advisory votes on the compensation of the Company’s named executive officers. Except as set forth in this Amendment, the disclosure contained in the Original Report remains unchanged.

### Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company has determined, in light of and consistent with the advisory vote of the Company’s stockholders as to the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers, to include a stockholder advisory vote on the compensation of the Company’s named executive officers in its annual meeting proxy materials once every year until the next advisory vote on the frequency of stockholder votes on the compensation of the Company’s named executive officers.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

By: **Fibrocell Science, Inc.**  
/s/ John M. Maslowski  
\_\_\_\_\_  
John M. Maslowski  
President and Chief Executive Officer

Date: September 26, 2019